Towards commercial allogeneic cell therapy manufacturing
Cell Gene Therapy Insights 2018; 4(11), 1153-1156.
Published: 18 December 2018
MARIA DEl PILAR REDONDO holds an MsC in Pharmacy, specializing in Pharmaceutical technology and analysis and control of drugs. Although she began her career at Pfizer within the area of Quality, she later focused on Pharmaceutical Development. After incorporation into the Pharmamar group in 2005, she became in charge of pharmaceutical development and production of investigational medicines for the treatment of Alzheimer’s disease. Pilar joined Tigenix SAU in June 2013 as Senior Director of Technical Operations. Her responsibilities included the overview and management of activities in the areas of Pharmaceutical Development (CMC/Industrialization) and Manufacturing of the stem cell platform.